PKM and cancer: The fact that Wnt activators-independent CRC organoids had mutations in the Wnt signaling pathway (e.g., Apc, Ctnnb1, and Tcf7l2)39, suggests that cancer cells from PKM2-deficient mice might carry those mutations.